ValueAct CEO says Valeant does not need to buy Allergan: Reuters
ValueAct Capital, a top shareholder in Valeant Pharmaceuticals International Inc, supports the company's independent business plan and does not believe the Canadian drugmaker has to buy Allergan Inc, the investor told Reuters. ValueAct likes a potential combination between Valeant and Allergan, but said a drawn-out bidding war for the Botox maker might be too distracting. Allergan is fighting a hostile US$52 billion bid from Valeant and William Ackman, head of hedge fund Pershing Square Capital Management.
12 August 2014•2 mins read
